$2.94
-0.08-2.65%
At Close: -
$3.02
0.082.72%
After Hours: Jul 2, 4:00 PM EDT
15 minutes delayed
Poseida Therapeutics
PSTXNASDAQ
Poseida Therapeutics (NASDAQ:PSTX) Stock, Analyst Ratings, Price Targets, Predictions
Poseida Therapeutics Inc has a consensus price target of $16.6, established from looking at the 17 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on May 22, 2024, May 2, 2024, and April 22, 2024. With an average price target of $20 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 562.25% upside for Poseida Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
Cantor Fitzgerald
HC Wainwright & Co.
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Poseida Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/22/2024 | Buy Now | 562.25% | HC Wainwright & Co. | Arthur He | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 562.25% | HC Wainwright & Co. | Arthur He | → $20 | Reiterates | Buy → Buy | Get Alert |
| 04/22/2024 | Buy Now | 562.25% | HC Wainwright & Co. | Arthur He | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | Buy Now | 562.25% | HC Wainwright & Co. | Arthur He | → $20 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2023 | Buy Now | 231.13% | Piper Sandler | Edward Tenthoff | $8 → $10 | Maintains | Overweight | Get Alert |
| 12/11/2023 | Buy Now | 562.25% | HC Wainwright & Co. | Arthur He | $15 → $20 | Maintains | Buy | Get Alert |
| 10/10/2023 | Buy Now | 363.58% | Cantor Fitzgerald | Jennifer Kim | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 08/08/2023 | Buy Now | 396.69% | HC Wainwright & Co. | Arthur He | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2023 | Buy Now | 396.69% | HC Wainwright & Co. | Arthur He | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | 396.69% | HC Wainwright & Co. | Arthur He | → $15 | Reiterates | → Buy | Get Alert |
| 03/10/2023 | Buy Now | 396.69% | HC Wainwright & Co. | Arthur He | → $15 | Reiterates | → Buy | Get Alert |
| 02/23/2023 | Buy Now | 396.69% | HC Wainwright & Co. | Arthur He | → $15 | Maintains | Buy | Get Alert |
| 02/01/2023 | Buy Now | 694.7% | Cantor Fitzgerald | Jennifer Kim | → $24 | Reiterates | → Overweight | Get Alert |
| 01/04/2023 | Buy Now | 396.69% | HC Wainwright & Co. | Swayampakula Ramakanth | → $15 | Initiates | → Buy | Get Alert |
| 08/09/2022 | Buy Now | 264.24% | Piper Sandler | Edward Tenthoff | $9 → $11 | Maintains | Overweight | Get Alert |
| 05/13/2022 | Buy Now | 198.01% | Piper Sandler | Edward Tenthoff | $19 → $9 | Maintains | Overweight | Get Alert |
| 01/07/2022 | Buy Now | 694.7% | Cantor Fitzgerald | Brian Cheng | → $24 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Poseida Therapeutics (PSTX) stock?
The latest price target for Poseida Therapeutics (NASDAQ:PSTX) was reported by HC Wainwright & Co. on May 22, 2024. The analyst firm set a price target for $20.00 expecting PSTX to rise to within 12 months (a possible 562.25% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Poseida Therapeutics (PSTX)?
The latest analyst rating for Poseida Therapeutics (NASDAQ:PSTX) was provided by HC Wainwright & Co., and Poseida Therapeutics reiterated their buy rating.
When was the last upgrade for Poseida Therapeutics (PSTX)?
There is no last upgrade for Poseida Therapeutics
When was the last downgrade for Poseida Therapeutics (PSTX)?
There is no last downgrade for Poseida Therapeutics.
When is the next analyst rating going to be posted or updated for Poseida Therapeutics (PSTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Poseida Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Poseida Therapeutics was filed on May 22, 2024 so you should expect the next rating to be made available sometime around May 22, 2025.
Is the Analyst Rating Poseida Therapeutics (PSTX) correct?
While ratings are subjective and will change, the latest Poseida Therapeutics (PSTX) rating was a reiterated with a price target of $0.00 to $20.00. The current price Poseida Therapeutics (PSTX) is trading at is $3.02, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.